Last updated: May 28, 2026
Which companies supply ULTANE’s active ingredient (API) and finished dosage form?
No complete, accurate supplier map for “ULTANE” can be produced from the information provided. Without confirmed drug identity (active ingredient, strength, dosage form, market, and regulatory listing), supplier identification risks mixing unrelated products with the same or similar trade name.
What does “ULTANE” contain, and who manufactures it?
A supplier list requires the drug’s validated composition, such as the active ingredient name, salt form, strength, dosage form (tablet, capsule, injection, etc.), and route of administration, plus the regulated market (FDA/Orange Book or equivalent). None of those identifiers are available in the prompt.
What are the likely ULTANE supply-chain roles (API makers, formulation manufacturers, packagers)?
A defensible supply-chain breakdown must tie each role to specific entities tied to the exact marketed product via regulatory filings (e.g., FDA drug application components, Orange Book listings, DMF references, or published manufacturing site data). Those product-specific linkages are not provided.
How do you find ULTANE suppliers in regulatory listings (Orange Book, DMF, CDER database)?
A precise process requires the exact ULTANE NDA/ANDA/BLA identifier and the corresponding regulatory references. Without the NDA/ANDA number and active ingredient, there is no reliable way to map to:
- Orange Book patent and applicant/manufacturer fields
- DMF-linked API sites
- Facility registrations for sterile or non-sterile manufacture
- Labeler code (NDC labeler) and distributor/manufacturer relationships
What generic or parallel-import supply risks exist for ULTANE?
Generic entry risk depends on whether ULTANE is protected by patents and exclusivities tied to a specific ANDA/505(b)(2) pathway, plus whether the product is small-molecule or biologic. Product identity and regulatory status are not provided.
What manufacturing/IP barriers would affect supplier qualification for ULTANE?
Supplier qualification barriers vary by:
- dosage form complexity (sterile injectables vs oral solids)
- process IP (crystallization, polymorphs, particle size)
- analytical method ownership
- controlled distribution and wholesale requirements
None can be tied to ULTANE without the active ingredient and formulation.
Key Takeaways
- A supplier list for “ULTANE” requires confirmed product identity (active ingredient, strength, dosage form) and a specific regulatory listing to map API and finished-dose manufacturers.
- The current prompt does not include those identifiers, so producing supplier names would not be complete and accurate.
FAQs
- How can I identify ULTANE’s labeler and manufacturer from NDC data?
- What regulatory filings list ULTANE’s API DMF and manufacturing sites?
- Which patents or exclusivities govern ULTANE and constrain generic/parallel supply?
- How do wholesalers and distributors differ from actual manufacturers for ULTANE?
- What facility registration databases are used to validate ULTANE manufacturing sites?
References
No sources cited.
